Micafungin Rompharm

Micafungin, the active ingredient in Micafungin Rompharm, is an echinocandin antifungal presented as an intravenous solution for intravenous use. It treats invasive candidiasis and other serious Candida infections in immunocompromised patients.

GNH USA supplies Micafungin Rompharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is an echinocandin antifungal used to treat serious Candida infections.

Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. Esophageal candidiasis: resolves mucosal infection of the esophagus. Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection in high‑risk transplant recipients. Candida peritonitis and intra‑abdominal infections: used to manage intra‑abdominal Candida disease.

Micafungin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Fever or chills during infusion. - Nausea or vomiting. - Headache. - Rash or mild skin irritation. - Elevated liver enzymes. - Infusion‑related erythema.

Serious or Rare Side Effects: - Severe hepatic dysfunction or hepatitis. - Anaphylactic or severe allergic reactions. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Acute renal failure. - Severe hypotension or shock. - Eosinophilia with systemic symptoms.

Use of Micafungin requires careful clinical monitoring and adherence to safety guidelines. - Renal function: assess and monitor in patients with renal impairment. - Hepatic function: check liver enzymes before and during therapy. - Drug interactions: review concomitant medications for potential interactions. - Pregnancy: only use if the potential benefit justifies the potential risk to the fetus. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Micafungin can interact with several drug classes; clinicians should evaluate concomitant therapy.

Major Interactions (Avoid): - Cytochrome P450 inducers (e.g., rifampin): may reduce Micafungin exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase Micafungin levels. - Co‑administration with other echinocandins: risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals: potential additive hepatotoxicity. - Immunosuppressants such as tacrolimus or cyclosporine: monitor drug concentrations. - Nephrotoxic agents (e.g., aminoglycosides): observe renal function closely.